^
Association details:
| Biomarker: | MTOR E2419K |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib
Excerpt:
Examination of the sequencing data for biologically plausible mechanisms of sensitivity to everolimus or pazopanib revealed two mutations in mTOR, the target of everolimus.
DOI:
10.1158/2159-8290.CD-13-0353
Trial ID:
